Generic Name and Formulations:
Potassium citrate 5mEq (540mg), 10mEq (1080mg), 15mEq (1620mg); tabs.
Mission Pharmacal Company
- Eplerenone May Improve Cardiovascular Disease Risk in HIV
- Metabolic Influence of Metformin in Pregnant Women With PCOS
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- Oral and Transdermal Estrogen Dose Equivalents
- Combination Hypertension Treatments
- Beers List: Potentially Inappropriate Drugs for Elderly
Indications for UROCIT-K:
Renal tubular acidosis with calcium stones. Hypocitraturic calcium oxalate nephrolithiasis. Uric acid lithiasis.
Take within 30 minutes of meals or bedtime snack. Adjust based on urinary citrate levels and/or pH. Urinary citrate <150mg/day: 30mEq twice daily or 20mEq 3 times daily. Urinary citrate >150mEq/day: 15mEq twice daily or 10mEq 3 times daily. Max 100mEq/day.
See literature. Hyperkalemia or predisposing conditions. GI narrowing or stricture, delayed gastric emptying or predisposing conditions. Peptic ulcer disease. UTI. Renal insufficiency (GFR <0.7mL/kg per minute).
Restrict salt intake and encourage high fluid intake. Discontinue if severe vomiting, GI pain or bleeding occurs and follow-up. Monitor 24 hour urinary citrate, urinary pH, serum electrolytes, CBC, ECG, at least every 4 months; discontinue if hyperkalemia, significant rise in serum creatinine, or significant fall in hematocrit or hemoglobin occurs. Pregnancy (Cat.C). Nursing mothers.
Contraindicated with potassium-sparing diuretics, anticholinergics, other drugs that slow GI motility. Monitor digoxin. May interfere with some urinary tract antibiotics. Caution with drugs that raise serum potassium.
Hyperkalemia, GI upset, irritation, bleeding.
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight